A High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Is Obesity a Risk Factor for APL? Implication of Targeted Therapy to Control Obesity and APL Prevention.

Julianne Qualtieri(Vanderbilt University), Nishitha Reddy(Vanderbilt University), Gregory D. Ayers(Vanderbilt University Medical Center), M. J. Pradeep Kumar(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), John P. Greer(Vanderbilt University Medical Center), David R. Head(University of Southern California), Jason Tedesco(Vanderbilt University Medical Center)
Blood
November 20, 2009
10.1182/blood.v114.22.3099.3099
Cited by 0

Related Papers

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
|Blood|1997|869
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
|Journal of Clinical Oncology|1990|786